Skip to main content
Medical Reference · Condition Monograph

Breast Cancer

유방암

Breast cancer is a collective term for cancers that start in breast tissue.

History

Breast cancer is a collective term for cancers that start in breast tissue. In the past, many people visited a hospital only after a palpable lump in the breast had grown and the skin had become dimpled or ulcerated, so it was common for patients to already have advanced disease at diagnosis. For a long time surgery was close to the only treatment, and at one time extensive surgery removing the breast and surrounding tissue was regarded as the standard. Later, as the understanding took hold that cancer is not only a "local disease" but a disease that can spread throughout the body through the blood and lymph, it became clear that simply widening the extent of surgery was not enough.

Advances in imaging and pathological diagnosis changed the course of breast cancer care. As mammography and ultrasound became widespread, relatively small lesions could be found even at a stage without symptoms. As early diagnosis increased, survival rates were observed to improve substantially. At the same time, as the number of small lesions found by testing increased, it also began to be emphasized that not all lesions become dangerous at the same rate.

A major recent change is the perspective of viewing breast cancer not as "a single disease" but as several subtypes. Treatment choices and prognosis differ depending on which hormone signals the cancer cells respond to, whether a specific growth signal receptor is overexpressed, and what the immune environment is like. Recent studies have developed strategies such as shrinking the tumor with preoperative treatment to reduce the extent of surgery, or personalizing drug treatment to lower the risk of recurrence after surgery.

Causes

The cause of breast cancer is difficult to explain in a single way. In general, it can be understood as a process in which cells of the breast ducts (the tubes through which milk passes) or lobules (the glands that produce milk) accumulate genetic damage from various causes and, as a result, begin uncontrolled proliferation. The important point is that no "single food" or "single lifestyle habit" has been established as causing breast cancer, and it is common for risk to increase as several risk factors overlap.

The duration of hormone exposure is frequently mentioned as a factor related to breast cancer risk. The longer the breast is exposed to estrogen, as with early menarche or late menopause, the more the risk may increase. There are also reports that risk may differ when first childbirth is late or there has been no childbirth, or when breastfeeding is limited. Menopausal hormone therapy can increase risk in some situations, so an individual's symptoms and risk level must be considered together.

Among lifestyle factors, obesity, physical inactivity, and alcohol consumption have repeatedly been observed as factors that increase risk. Obesity after menopause in particular is often explained in connection with changes in the hormonal environment through body fat. Exposure to ionizing radiation (e.g., radiation for therapeutic purposes) can raise risk, and it is also known that in people with dense breasts, lesions may not only be obscured on testing but the risk itself may be higher.

Genetic Epidemiology

Genetic epidemiology deals with "how genetic factors change breast cancer risk in a population." Most breast cancers occur without a distinct hereditary disease, but some are strongly linked to family history and specific gene variants. Most notably, variants that genetically affect DNA repair function, such as BRCA gene variants, can greatly increase the risk of breast cancer.

When several family members have breast or ovarian cancer, when breast cancer occurred at a young age, when there is bilateral breast cancer, or when there is a family history of male breast cancer, genetic factors are considered more actively. In such situations, not only whether the individual undergoes genetic testing but also risk assessment for the whole family and screening strategies are discussed together.

Recent studies are discussing in more detail the methods and starting age of screening, and the appropriate candidates for preventive surgery or drug prevention, in people with genetic variants. It is important to understand genetic information as "one piece that explains risk" and to interpret it in combination with clinical information.

General Epidemiology

Breast cancer is known to be one of the most common cancers in women worldwide. However, incidence and mortality differ greatly depending on a country's access to health care, its screening system, and the level of resources available for treatment. In high-income countries, survival rates are reported to be relatively high because early diagnosis and access to treatment are comparatively good, whereas in resource-limited regions diagnosis is delayed and treatment is difficult, so the mortality burden can be greater.

Age is an important risk factor. Breast cancer tends to become more common with age, and its occurrence increases especially after middle age. However, it can also occur at a young age, and breast cancer in young people is sometimes more advanced at diagnosis or includes biologically aggressive subtypes, so a separate management perspective is needed.

Breast cancer also occurs rarely in men. Male breast cancer accounts for a small proportion of all breast cancers, but it can be associated with genetic factors or abnormalities in the hormonal environment, so care is needed at diagnosis. Recent studies have repeatedly reported that screening recommendations differ from country to country, so the pattern of diagnosis can differ even at the same age and risk level.

Pathogenesis

The pathogenesis of breast cancer can be explained as a process in which normal breast cells change into cancer cells through multiple genetic damages and environmental changes. The breast consists of ducts and lobules and the fatty and fibrous tissue surrounding them, and ductal epithelial cells or lobular cells are often the starting point of cancer. Initially there may be forms that remain only within the ducts or lobules, and when, over time, the cancer breaks through the basement membrane and invades surrounding tissue, it is classified as invasive breast cancer.

Hormone signals can play an important role in the growth of cancer cells. Some breast cancers respond to estrogen or progesterone signals, and in such cases hormone therapy becomes central to treatment. Some breast cancers can also grow rapidly because a specific growth signal receptor is excessively activated, and targeted therapy aimed at that receptor can be effective. Conversely, in subtypes without distinct specific markers, the role of chemotherapy and immunotherapy can become greater.

Recent studies hold that not only the cancer cells themselves but also the tumor microenvironment, the composition of immune cells, blood vessel formation, and metabolic changes may be involved in growth, metastasis, and treatment resistance. To explain why tumors of the same size can have different recurrence risks, attempts to integrate molecular classification and the immune environment are increasing.

Symptoms

Breast cancer often has no symptoms in its early stages. For this reason, it is more often found on screening than through symptoms. When symptoms appear, the most common is a new lump felt in the breast or armpit. The lump may be painless and may feel hard or have irregular borders when touched. However, not every breast lump is cancer, and benign nodules are also very common.

Changes in the shape of the breast are also important symptoms. One breast may suddenly enlarge, the nipple may newly turn inward, or the skin may thicken and dimple like an orange peel. Blood-tinged discharge from the nipple, or skin around the nipple that becomes red and peels and does not heal well, also requires attention.

When the disease has progressed and spread to other areas, symptoms such as bone pain, shortness of breath, a persistent cough, and symptoms related to abnormal liver function may appear. However, because these symptoms are also common in other diseases, they must be evaluated by considering the overall situation together with the breast symptoms.

Signs

Signs are objective findings that the examiner can confirm. The most common signs on examination are a mass in the breast or enlarged lymph nodes in the armpit. Skin dimpling, orange-peel changes, nipple retraction, nipple discharge, and localized redness and scaly changes of the breast skin may be observed. In rare but aggressive types such as inflammatory breast cancer, the whole breast may become red and swollen with a sensation of warmth, so care is needed so that it is not mistaken for simple inflammation.

Imaging signs are very important. On mammography, the shape and distribution of calcifications, the borders of a mass, and architectural distortion can be clues. On ultrasound, the shape of the mass, its internal echoes, blood flow, and findings of invasion of surrounding tissue are evaluated. Magnetic resonance imaging can help in screening high-risk groups or evaluating the extent of lesions.

Pathological signs are the key to a definitive diagnosis. Biopsy confirms the shape and degree of differentiation of the cancer cells and whether there is invasion, and treatment direction is determined through marker tests such as hormone receptor and growth signal receptor expression. Recent studies show that the range in which additional molecular tests and gene expression-based tests are used to evaluate recurrence risk and the need for treatment is expanding.

Screening

The goal of breast cancer screening is to find cancer before symptoms develop, improve treatment outcomes, and reduce the need for larger surgery or more intensive treatment. The most widely used screening test in the average-risk group is mammography. However, the starting age and testing interval differ according to national and professional society recommendations. Recent studies generally regard the 40s through the early 70s as the main target ages, and it is often summarized that the benefit of screening is clear in people in their 50s and 60s.

High-risk groups (strong family history, specific genetic variants, history of prior chest radiation therapy, etc.) need a different strategy from the average-risk group. In these cases, screening starts at an earlier age, and breast magnetic resonance imaging is sometimes used in addition to mammography. In people with dense breasts, lesions can be obscured on mammography alone, so discussion continues about considering ultrasound or other supplementary tests.

The role of breast self-examination and clinical examination is debated, so it is realistic to understand them as serving to "recognize symptoms" and "connect to care" rather than as stand-alone screening tools. Ultimately, it is important to plan screening according to individual risk and to undergo it consistently while understanding the advantages and disadvantages of testing.

Diagnosis

Breast cancer diagnosis usually proceeds in the sequence "detection of an abnormal finding → evaluation by imaging → confirmation by biopsy → staging." An abnormal finding may be discovered on screening or when the patient feels a lump or skin change. Imaging is based on mammography and ultrasound, and magnetic resonance imaging is added as needed.

The diagnosis is confirmed by biopsy. A sample of the lesion is obtained by needle biopsy and examined under a microscope, and at the same time hormone receptors, growth signal receptors, proliferation indices, and other factors are evaluated. If lymph node metastasis is suspected, ultrasound and biopsy of the armpit lymph nodes may be performed together.

Staging is the process of checking the tumor size, lymph node metastasis, and distant metastasis to plan treatment. Recent studies show that the range in which tests such as gene expression-based tests are used to decide the need for chemotherapy after surgery is expanding, in line with the move to reduce overtreatment.

Treatment

Breast cancer treatment combines surgery, radiation therapy, and drug therapy (chemotherapy, hormone therapy, targeted therapy, immunotherapy). Which treatments to use and in what order is decided by considering the stage and subtype, the patient's age and comorbidities, and the patient's preferences together. Surgery is the center of local treatment. Breast-conserving surgery removes only the tumor and preserves as much of the breast as possible, and it is usually combined with radiation therapy. Mastectomy is surgery that removes breast tissue extensively, and reconstructive surgery may be discussed along with it.

Systemic treatment is key to lowering the risk of recurrence or controlling advanced disease. In hormone receptor-positive breast cancer, hormone therapy is a major pillar, and in types in which a growth signal receptor is overactivated, targeted therapy aimed at that receptor has improved treatment outcomes. The armpit lymph nodes are evaluated and treated with sentinel lymph node biopsy or lymph node dissection.

Recent studies report advances in antibody-drug conjugates, cell cycle-regulating drugs, immunotherapy, and other treatments, and the trend of expanding treatment options continues, especially in advanced disease. It has become important for treatment to move in the direction of doing "exactly as much as is needed" according to the subtype and individual risk, rather than simply doing "more."

Prognosis

The prognosis of breast cancer depends greatly on the stage and subtype. When it is found early and confined to the breast and nearby lymph nodes, treatment outcomes are good. When there is lymph node metastasis or metastasis to other organs, the prognosis differs, but as treatment advances, the group of patients who can expect long-term survival is also growing.

When discussing prognosis, not only the survival rate but also the risk of recurrence and quality of life must be considered together. Issues such as whether the breast is preserved, lymphedema, side effects after chemotherapy, symptoms from long-term hormone therapy, early menopause and osteoporosis, and cardiac toxicity can have long-term effects. That is why, recently, it has become important not only to do "more" treatment but to do "exactly as much as is needed."

Recent studies continue efforts to distinguish precisely, through molecular classification and gene expression-based risk assessment, which patients can safely have chemotherapy reduced or omitted and, conversely, which patients need more intensive treatment. This approach is a process of finding the balance point that prevents recurrence while reducing overtreatment.

Prevention

Breast cancer prevention can be broadly divided into "lifestyle habits that lower risk" and "risk-based screening and prevention strategies." In terms of lifestyle, weight management, regular exercise, and limiting alcohol have been observed to be helpful. In particular, obesity after menopause and alcohol consumption are repeatedly mentioned as factors that increase risk. Smoking increases the risk of various cancers, so quitting smoking is fundamental.

In high-risk groups, additional strategies are discussed. When a strong family history or a specific genetic variant is identified, earlier screening (mammography and magnetic resonance imaging, etc.) together with preventive drugs (e.g., selective estrogen receptor modulators) or preventive surgery may be considered. Because such choices require weighing benefits, side effects, and personal values together, genetic counseling and specialist consultation are important.

Screening is an important pillar of prevention. Strictly speaking, screening is closer to "reducing death and treatment burden through early detection" than to "preventing occurrence," but as a result it has the effect of lowering risk. Even in the average-risk group, undergoing testing consistently at the recommended ages and intervals is the most realistic prevention strategy.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.